Pfizer (PFE), on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical (BHVN), has agreed to pay $59,746,277 to resolve allegations that, prior to Pfizer’s acquisition of the company, Biohaven knowingly caused the submission of false claims to Medicare and other federal health care programs by paying kickbacks to health care providers to induce prescriptions of Biohaven’s drug Nurtec ODT.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Viking Therapeutics (VKTX) Stock Could Rise 200%, Says Jefferies
- Morgan Stanley Backs Chipmaker Qorvo after Starboard Stake
- Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards
- Ex-Dividend Date Nearing for These 10 Stocks – Week of January 20, 2025
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations